SBIR-STTR Award

Phase II Of Verofy: a New Tool to Improve Productivity for Stress Research
Award last edited on: 9/30/14

Sponsored Program
SBIR
Awarding Agency
NIH : NCCAM
Total Award Amount
$1,633,720
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Paul D Slowey

Company Information

Oasis Diagnostics Corporation (AKA: Bamburgh Medical)

15720 NE 31st Avenue
Vancouver, WA 98686
   (360) 546-1563
   info@4saliva.com
   www.4saliva.com
Location: Single
Congr. District: 03
County: Clark

Phase I

Contract Number: 1R43AT006634-01
Start Date: 8/1/11    Completed: 2/28/12
Phase I year
2011
Phase I Amount
$325,567
This Phase 1 NIH SBIR proposal is for support of an interdisciplinary program involving the Oasis Diagnostics(R) Corporation, Madison Biodiagnostics, LLC, and the University of New Orleans who seek to collaboratively demonstrate an innovative saliva collection and analysis system (VerOFy(R)) for measurement of cortisol levels at the point of sampling for measurement of real time stress response in the clinical laboratory. The innovative VerOFy(R) Rapid, Oral Fluid Test Platform (US PN 7,618,591) is an integrated sample collection and laboratory processing system that collects saliva by means of a proprietary absorbent pad connected to immunochromatographic test strips that produce a series of signal lines on the test strips correlating with varying cortisol levels in the acquired saliva sample within minutes of sample collection. Stress related research burgeoned to $22 million funded by NIH per year. Substantial research advancements were made after the stress hormone cortisol could be noninvasively measured in saliva. Salivary cortisol is arguably the most common biomarker used in a broad range of research protocols targeted at stress related illnesses. The present proposal pursues a significant advancement in stress research with the potential for advancing the field much like saliva testing did. Real time point of care cortisol measurement capability using the VerOFy(R) technology represents a substantial productivity improvement and cost reduction for stress responsiveness research. We estimate that between 30% and 50% of the $22 million expended for this research each year by NIH may produce little or questionable research benefit in current practice and would be potentially saved by use of the VerOFy(R) device. VerOFy(R) opens up new, unexplored possibilities within the stress research and related fields to tailor or individualize protocols for each individual including the rapid determination of stress non-responders. It further represents an opportunity for a standardized approach to cortisol measurements in stress related research. The cost and time benefits of this innovation will extend to $22 million of NIH funded research programs which rely upon the measurement of cortisol levels to identify stress responsiveness, bringing substantial cost reductions and productivity improvements to NIH funded stress related research. Phase 1 will demonstrate validation of the VerOFy(R) technology against standard control solutions of cortisol. Phase 2 of this program will demonstrate the effectiveness of this new method in improving research results and lowering the costs of stress related research.

Public Health Relevance:
NIH funds $22 million of stress related research which is dependent upon measurement of the biomarker cortisol as an indicator of stress response. Variation in current cortisol detection methods makes it impossible to individualize experimental protocols and compare results from different research programs. The present proposal uses an innovative salivary diagnostic device (VerOFy(R)) to standardize cortisol measurements and to lower stress related research costs.

Thesaurus Terms:
Absorbent Pads;Address;Aeroseb-Hc;Blood Capillaries;Capillaries;Cell Communication And Signaling;Cell Signaling;Cetacort;Chemotherapy-Hormones/Steroids;Clinical;Collection;Commit;Communities;Cort-Dome;Cortef;Cortenema;Cortisol;Cortispray;Cortril;Dermacort;Detection;Devices;Diagnostic;Direct Costs;Effectiveness;Eldecort;Endocrine Gland Secretion;Engineering;Flr;Failure (Biologic Function);Funding;Future;Hormones;Housing;Hydrocortisone;Hydrocortone;Hytone;Individual;Individual Differences;Intracellular Communication And Signaling;Investigators;Loinc Axis 4 System;Laboratories;Lateral;Liquid Substance;Manufactured Materials;Measurement;Measures;Mental Health;Mental Hygiene;Methods;Modeling;Nih;National Institutes Of Health;Nutracort;Oral;Participant;Phase;Plastics;Pregn-4-Ene-3,20-Dione, 11,17,21-Trihydroxy-, (11beta)-;Process;Proctocort;Product R;Production;Productivity;Protocol;Protocols Documentation;Psychological Health;Reporting;Research;Research Personnel;Researchers;Risk;Sbir;Sbirs (R43/44);Saliva;Salivary;Sampling;Series;Shipping;Ships;Signal Transduction;Signal Transduction Systems;Signaling;Small Business Innovation Research;Small Business Innovation Research Grant;Solutions;Stimulus;Stress;System;Systems Analyses;Systems Analysis;Technology;Testing;Therapeutic Hormone;Therapeutic Hydrocortisone;Time;United States National Institutes Of Health;Universities;Use Effectiveness;Validation;Variant;Variation;Biological Adaptation To Stress;Biological Signal Transduction;Biomarker;Capillary;Cost;Expectation;Failure;Fluid;Hypothalamic-Pituitary-Adrenal (Hpa) Axis;Hypothalamic-Pituitary-Adrenal Axis;Hypothalmus-Pituitary-Adrenal Axis;Improved;Indexing;Innovate;Innovation;Innovative;Liquid;Meetings;Physical Conditioning;Physical Health;Point Of Care;Programs;Prototype;Reaction;Crisis;Response;Saliva Diagnostic;Salivary Diagnostics;Sample Collection;Specimen Collection;Stem;Stress Response;Stress;Reaction;Success;Tool

Phase II

Contract Number: 2R44AT006634-02
Start Date: 8/1/11    Completed: 5/31/15
Phase II year
2013
(last award dollars: 2014)
Phase II Amount
$1,308,153

This Phase II SBIR builds upon the activities of R43-AT006634, "VerOFy: A New Tool to Improve Productivity and Reduce Costs for Stress Research". Technology for an integrated sample collection system was developed which non-invasively measures salivary cortisol levels within minutes of sample collection; this is a substantial improvement over traditional immunoassays in which cortisol concentrations are not returned for days to months. This innovation is expected to have a large impact on stress research as cortisol changes frequently and critical information about stress is lost during this measurement specific time-delay. VerOFy(R) is also innovative as it decreases costs compared to traditional protocols which require samples to be assayed regardless of their utility. Thus, real-time point-of-care cortisol measurement using the VerOFy(R) technology represents a substantial productivity improvement and major cost reduction for stress research. Phase I activities were accomplished well within the allotted Project timeframe. Furthermore, the technology was advanced substantially beyond initial goals by testing the system with pilot samples from human participants and developing the technology into a fully quantitative format capable of measuring salivary cortisol in real-time in conjunction with a complementary innovation for signal line analysis, known as the Lightbox Image Analysis Module (LIAMTM) portable reader. These added activities were pursued in order to comprehensively respond to Phase I critiques. Proposed Phase II activities extend these activities substantially further by (1 finalizing quality control of the VerOFy(R) device (e.g., determining recovery, sensitivity, precision, etc); (2) validating the LIAMTM reader for real-time quantitative cortisol results by streamlining the reader process and exploring user-friendly technological advances with a smartphone application; and (3) validating both the VerOFy(R) and LIAMTM with human participants in an established setting as well as six beta-sites strategically selected to represen each region of the US and cover a range of expertise for product evaluation. In parallel to these research activities, a detailed commercialization plan is described in which this technology can be feasibly marketed, building from the prior experience of the investigative team and advisory board of researchers and relevant experts. By the end of phase II, the goal is to have a fully operational VerOFy(R) device to allow stress researchers to individualize protocols for each individual and rapidly determine stress responsively via salivary cortisol. Future directions illustrate plans to move the technology forward beyond the Research Use Only application, as the team has accomplished with prior technology. VerOFy(R) opens up new, unexplored possibilities within the stress field. The impact of this technology can be tremendous as the annual economic toll of stress-related illnesses and health problems exceed $200 billion in the US and the NIH funded $83 million of stress-related research which utilizes salivary cortisol already in 2012 alone.

Public Health Relevance Statement:


Public Health Relevance:
NIH funds millions of stress-related research which relies on the biomarker cortisol as an indicator of stress responsivity and health risk. Current cortisol detection methods makes it impossible to individualize experimental protocols or provide feedback to the participant or researcher as cortisol assay results are not obtained for days to months. The present proposal uses an innovative salivary diagnostic device and reader to quantitatively measure salivary cortisol in real-time and lower stress-related research costs.

Project Terms:
absorption; Acute; acute stress; base; Biological Assay; Biological Markers; Biotin; Blinded; Budgets; Buffers; Child; Clinical; Clinical Protocols; Collection; commercialization; Computer software; Computers; cost; Critiques; cross reactivity; Data; Data Collection; Detection; Development; Devices; Discipline; dissemination research; Economics; Engineering; Enzymes; Evaluation; experience; Feedback; file format; Filtration; Funding; Future; Goals; Grant; Hand; Health; Human; human subject; Hydrocortisone; Image; Image Analysis; Immunoassay; impression; improved; Individual; Individual Differences; innovation; Institutes; Laboratories; Lateral; Letters; Marketing; Measurement; Measures; Medical; meetings; Mental Health; Mentally Ill Persons; Methods; Minority; Modeling; National Center for Complementary and Alternative Medicine; National Heart, Lung, and Blood Institute; National Institute of Child Health and Human Development; National Institute of Drug Abuse; National Institute of Mental Health (U.S.); National Institute on Alcohol Abuse and Alcoholism; new technology; Outcome; Participant; Performance; Phase; physical conditioning; point of care; Population; Problem behavior; Process; Product R; Production; Productivity; Protocols documentation; prototype; public health relevance; Quality Control; Reader; Reading; Recovery; Reporting; Research; Research Activity; Research Personnel; Research Support; response; Risk; Saliva; saliva diagnostic; Salivary; sample collection; Sampling; Shipping; Ships; Signal Transduction; Site; Small Business Innovation Research Grant; Stress; stressor; System; Technology; Telephone; Testing; Time; time use; tool; United States National Institutes of Health; user-friendly